Sarepta Therapeutics Annual Income Statement (NASDAQ:SRPT)

Add to My Stocks
$29.68 $0.51 (1.69%) SRPT stock closing price Mar 23, 2017 (Closing)

Financial analysis of Sarepta Therapeutics involves more than just checking the Sarepta Therapeutics stock price, by looking at the financial statements of the company in detail. In the income statement, an investor can check for important parameters like the topline, the bottomline, the EPS basic, dividends etc. Like any other income statement, the SRPT income statement also itemizes revenue, operating expenses, and profits for a quarter or year and reflects a YoY revenue decline of $8.5M when compared to the same period in the past. Along with Sarepta Therapeutics assets and Sarepta Therapeutics free cash flow, profits as shown in profit and loss statement give key insights about the business. The profits have decreased from $-135.78M YoY and 2015 revenue is $1.25M. Sarepta Therapeutics revenue for 2015 is $1.25M. View revenue and profit details for latest and last 10 financial years.

show more
Annual
Quarterly
View Previous Years
View Next Years
Fiscal year is Jan - Dec. 2015 2014 2013 2012 2011 2010 2009 2008 2007
Sarepta Therapeutics Net Sales or Revenues
1.25M9.75M14.21M37.32M46.99M29.42M17.58M21.25M10.98M
Cost Of Goods Sold (COGS)---------
Sarepta Therapeutics Gross Profit
1.25M9.75M14.21M37.32M46.99M29.42M17.58M21.25M10.98M
Research & Development Expense146.39M94.23M72.9M52.4M66.86M35.97M24.39M38.91M34.76M
Selling General & Admin Expense75.04M49.31M31.59M14.63M16.05M14.38M8.69M9.79M9.33M
Income Before Depreciation Depletion Amortization-220.18M-133.78M-90.28M-29.7M-35.92M-20.93M-15.5M-27.45M-33.1M
Depreciation Depletion Amortization---------
Non Operating Income0.15M-2M-21.7M-91.58M33.6M-11.24M-9.65M3.5M5.93M
Interest Expense---------
Sarepta Therapeutics Pretax Income
-220.03M-135.78M-111.98M-121.28M-2.31M-32.17M-25.15M-23.95M-27.16M
Provision for Income Taxes---------
Minority Interest---------
Investment Gains Losses---------
Other Income---------
Income Before Extraordinaries & Disc Operations-220.03M-135.78M-111.98M-121.28M-2.31M-32.17M-25.15M-23.95M-27.16M
Extraordinary Items & Discontinued Operations---------
Sarepta Therapeutics Net Income (Profit/Loss)
-220.03M-135.78M-111.98M-121.28M-2.31M-32.17M-25.15M-23.95M-27.16M
Average Shares used to compute Diluted EPS42.29M40.03M33.85M23.6M21.6M18.54M15.52M11.58M8.99M
Average Shares used to compute Basic EPS42.29M40.03M33.85M23.6M21.6M18.54M15.52M11.58M8.99M
Income Before Nonrecurring Items-220.03M-133M-89.19M-29.35M-2.32M-32.17M-25.16M-23.95M-27.17M
Income from Nonrecurring Items--2.79M-22.79M-91.94M-----
Sarepta Therapeutics Earnings Per Share Basic Net
-5.20-3.39-3.31-5.14-0.12-1.74-1.62-2.04-3.00
Sarepta Therapeutics Earnings Per Share Diluted Net
-5.20-3.39-3.31-5.14-0.12-1.74-1.62-2.04-3.00
EPS Diluted Before Nonrecurring Items-5.20-3.32-2.64-1.24-0.12-1.74-1.62-2.04-3.00
Preferred Dividends Acc Pd---------
Dividends Common---------
Dividend Per Share Common---------
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years
Get Income statement for another ticker

1:11
SRPT
Sarepta Therapeutics stock analysis involves checking at least a few of the important things like:
  • Topline: A growing topline, as seen from the Sarepta Therapeutics revenue chart, as is not the case with Sarepta Therapeutics indicates a sagging business. One needs to compare the QoQ or YoY topline growth of SRPT stock with its peers like DBVT stock and HALO stock to see if the growth compares well with what can be expected for a company in that industry.
  • Bottom line: Most businesses like Sarepta Therapeutics try to improve their bottom line by growing their topline and by increasing their operating efficiency. A healthy bottom line growth implies a good investment.
The income statement is also called statement of revenue and expense. The financials along with Sarepta Therapeutics historical stock prices provides a lot of details about the firm. .